MCID: INT079
MIFTS: 51

Intrahepatic Cholangiocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 20 6 15 17 70
Cholangiocarcinoma 44 70
Peripheral Intrahepatic Cholangiocarcinoma 70
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
MeSH 44 D018281
NCIt 50 C35417
SNOMED-CT 67 109842005
ICD10 32 C22.1
UMLS 70 C0206698 C0345905 C3273048

Summaries for Intrahepatic Cholangiocarcinoma

GARD : 20 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to mucinous intrahepatic cholangiocarcinoma and sarcomatous intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is CPS1-IT1 (CPS1 Intronic Transcript 1), and among its related pathways/superpathways are mTOR signaling pathway (KEGG) and Central carbon metabolism in cancer. The drugs Celecoxib and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and pancreas, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 776)
# Related Disease Score Top Affiliating Genes
1 mucinous intrahepatic cholangiocarcinoma 33.0 KRT7 IDH1
2 sarcomatous intrahepatic cholangiocarcinoma 32.9 KRT7 KRT19 AFP
3 cholangiocarcinoma 32.4 TUG1 TP53 RASGEF1A MUC4 KRT7 KRT19
4 klatskin's tumor 32.1 TP53 KRT7 KRT19 IDH1 CPS1-IT1 AFP
5 adenocarcinoma 31.4 TP53 MUC4 KRT7 KRAS FGFR2 APC
6 bile duct adenoma 31.3 TP53 KRT7 KRT19
7 adenoma 31.2 TP53 KRT7 KRAS APC
8 cholangitis, primary sclerosing 31.1 KRT7 KRT19 AFP
9 bile duct cysts 31.0 KRT7 KRT19 KRAS AFP
10 hemangioma 31.0 TP53 KRT7 KRAS IDH2 IDH1
11 papillary adenocarcinoma 31.0 TP53 KRT7 KRT19
12 colorectal adenocarcinoma 30.8 TP53 KRT7 KRAS APC
13 bile duct cancer 30.7 TP53 MUC4 MIR424 KRT7 KRT19 KRAS
14 gallbladder cancer 30.7 TUG1 TP53 KRAS CCAT1
15 adenosquamous carcinoma 30.6 TP53 MUC4 KRT7 KRT19 KRAS
16 bile duct cystadenocarcinoma 30.6 KRT7 AFP
17 adenofibroma 30.6 TP53 KRT7 KRT19
18 angiosarcoma 30.6 TP53 KRT7 KRAS
19 signet ring cell adenocarcinoma 30.5 TP53 KRT7 KRAS
20 rectum adenocarcinoma 30.5 TP53 KRT7 KRAS
21 ampulla of vater cancer 30.5 TP53 KRT7 KRAS
22 rectum cancer 30.5 MIR424 MIR214 KRAS APC
23 intrahepatic bile duct adenoma 30.5 TP53 KRT7 KRT19 AFP
24 appendix adenocarcinoma 30.5 KRT7 KRAS
25 mucinous adenocarcinoma 30.5 TP53 KRT7 KRT19 KRAS
26 carcinosarcoma 30.5 TP53 KRT7 KRAS
27 squamous cell carcinoma 30.4 TUG1 TP53 KRT7 KRT19 FGFR2 CCAT2
28 fibrolamellar carcinoma 30.4 KRT7 KRT19 FGFR2 AFP
29 gastric adenocarcinoma 30.4 TP53 KRAS FGFR2 APC AFP
30 bile duct disease 30.4 TP53 MIR424 KRT7 KRT19 KRAS IDH1
31 thyroid gland cancer 30.4 TP53 KRT7 KRT19 KRAS
32 biliary tract benign neoplasm 30.3 TP53 KRT7 KRT19 KRAS AFP
33 biliary tract disease 30.2 TP53 MIR424 KRT7 KRT19 KRAS IDH2
34 hepatoblastoma 30.2 TUG1 TP53 KRT7 KRT19 APC AFP
35 intrahepatic biliary papillomatosis 30.2 KRAS AFP
36 transverse colon cancer 30.2 KRT7 KRAS
37 skin melanoma 30.1 TP53 MIR214 KRAS IDH1
38 esophageal cancer 30.1 TP53 MUC4 KRT19 KRAS FGFR2 CCAT1
39 bronchiolo-alveolar adenocarcinoma 30.1 MUC4 KRT7 KRAS
40 dysgerminoma 30.1 KRT7 FGFR2 AFP
41 small intestine cancer 30.1 TP53 KRT7 KRAS
42 myh-associated polyposis 30.1 KRAS APC
43 villous adenoma 30.1 TP53 KRT7 KRAS APC
44 osteogenic sarcoma 30.1 TUG1 TP53 CCAT2 CCAT1
45 thyroid gland follicular carcinoma 30.0 TP53 KRT7 KRT19 KRAS
46 gallbladder disease 30.0 TP53 KRT7 KRAS AFP
47 breast adenocarcinoma 30.0 TP53 KRT7 KRAS IDH1
48 endometrial cancer 29.9 TUG1 TP53 KRT7 KRAS FGFR2 CCAT1
49 brain cancer 29.9 TP53 IDH2 IDH1 APC
50 lung squamous cell carcinoma 29.9 TUG1 TP53 KRT19 KRAS FGFR2 CCAT2

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain; malaise

GenomeRNAi Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.4 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.4 AFP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.4 APC
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.4 AFP APC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.4 APC
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.4 AFP
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.4 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.4 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.4 APC
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-74 9.4 APC
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.4 AFP

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AFP APC FGFR2 IDH2 KRAS KRT19

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Etomidate Approved Phase 4 33125-97-2 36339 667484
6
Meperidine Approved Phase 4 57-42-1 4058
7 Anti-Inflammatory Agents Phase 4
8
Bilirubin Phase 4 635-65-4 5280352
9 Cyclooxygenase Inhibitors Phase 4
10 Cyclooxygenase 2 Inhibitors Phase 4
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4
12 Anesthetics, Inhalation Phase 4
13 Platelet Aggregation Inhibitors Phase 4
14 Anesthetics Phase 4
15
Bismuth Phase 4 7440-69-9 16682734 105143
16 Omega 3 Fatty Acid Phase 4
17 Ulipristal acetate Phase 4 126784-99-4
18 Analgesics Phase 4
19 Hypnotics and Sedatives Phase 4
20 GABA Modulators Phase 4
21 Psychotropic Drugs Phase 4
22 Narcotics Phase 4
23 Anesthetics, General Phase 4
24 Analgesics, Opioid Phase 4
25 Anesthetics, Intravenous Phase 4
26 Anti-Anxiety Agents Phase 4
27
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
28
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
29
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
30
leucovorin Approved Phase 2, Phase 3 58-05-9 6006
31
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
32
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
33
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 3 14769-73-4 26879
34
nivolumab Approved Phase 3 946414-94-4
35
Ipilimumab Approved Phase 3 477202-00-9
36
Ivosidenib Approved, Investigational Phase 3 1448347-49-6 71657455
37
Gemcitabine Approved Phase 3 95058-81-4 60750
38
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
39
Citalopram Approved Phase 3 59729-33-8 2771
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
41
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
42
Dexetimide Withdrawn Phase 3 21888-98-2
43 Vitamin B9 Phase 2, Phase 3
44 Folate Phase 2, Phase 3
45 Calcium, Dietary Phase 2, Phase 3
46 Antibiotics, Antitubercular Phase 3
47 Anti-Bacterial Agents Phase 3
48 Hematinics Phase 3
49 Folfirinox Phase 2, Phase 3
50 Emetics Phase 3

Interventional clinical trials:

(show top 50) (show all 529)
# Name Status NCT ID Phase Drugs
1 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
2 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
3 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
4 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
5 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
6 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
7 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
8 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
9 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
10 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
11 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study. Recruiting NCT04378023 Phase 4 Neoadjuvant Chemo-radiotherapy
13 Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
14 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial Unknown status NCT00653978 Phase 3
15 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
16 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
17 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
18 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
19 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
20 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
21 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
22 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
23 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
24 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
25 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
26 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Completed NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
27 Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT03771846 Phase 3 irinotecan, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
28 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
29 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
30 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Recruiting NCT02108145 Phase 2, Phase 3
31 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
32 A Randomized Controlled, Multicenter, Open, Seamless Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors Recruiting NCT04669496 Phase 2, Phase 3 Neoadjuvant treatment
33 Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency Recruiting NCT03345303 Phase 3 Bortezomib
34 The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
35 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
36 Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
37 A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3 Recruiting NCT04093362 Phase 3 TAS-120;Cisplatin/Gemcitabine
38 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
39 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
40 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Recruiting NCT04066491 Phase 2, Phase 3 Bintrafusp alfa;Placebo;Gemcitabine;Cisplatin
41 A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
42 Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
43 Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Active, not recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
44 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Active, not recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
45 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Active, not recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
46 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Active, not recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
47 Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma Terminated NCT02200042 Phase 3
48 Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
49 Photodynamic Therapy for Palliation of Unresectable Cholangiocarcinoma A Multicenter, Open Label, Randomized, Controlled Phase III Trial Terminated NCT00907413 Phase 3
50 Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas - A Prospective, Multicentric and Randomized Study. Terminated NCT00540735 Phase 3

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

40
Liver, Lymph Node, Pancreas, Colon, Neutrophil, Endothelial, Thyroid

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 13281)
# Title Authors PMID Year
1
MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. 61 47
19755794 2009
2
Piezo 1 activation facilitates cholangiocarcinoma metastasis via Hippo/YAP signaling axis. 61
33767919 2021
3
Ectopic expression of microRNA-874 represses epithelial mesenchymal transition through the NF-κB pathway via CCNE1 in cholangiocarcinoma. 61
33476715 2021
4
Protein-loss of SWI/SNF-complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma. 61
33747206 2021
5
Investigation of possible alternate animal reservoir hosts of Opisthorchis viverrini. 61
33524385 2021
6
Hepatobiliary morbidities detected by ultrasonography in Opisthorchis viverrini-infected patients before and after praziquantel treatment: a five-year follow up study. 61
33548204 2021
7
Systemic treatment of HCC in special populations. 61
33248171 2021
8
Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. 61
33316425 2021
9
Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011). 61
33382910 2021
10
Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. 61
33748727 2021
11
Outcome of bile leakage following liver resection with hepaticojejunostomy for liver cancer. 61
33471344 2021
12
Nuclear PTEN and p53 suppress stress-induced liver cancer through distinct mechanisms. 61
33667713 2021
13
Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. 61
33650998 2021
14
A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery. 61
32350718 2021
15
Resting energy expenditure in cancer patients: Agreement between predictive equations and indirect calorimetry. 61
33745594 2021
16
TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. 61
33221352 2021
17
Implication of CD69+ CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma. 61
33548061 2021
18
A Tool for Patient-Focused Care Regarding Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma. 61
33417116 2021
19
Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. 61
33212090 2021
20
Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis. 61
33608929 2021
21
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). 61
33210382 2021
22
Surgical ampullectomy with resection of the common bile duct for biliary papillomatosis. 61
33237486 2021
23
A novel management of gastric outlet obstruction where endoscopic retrograde cholangiopancreatography is required. 61
33797798 2021
24
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class. 61
33375902 2021
25
ASO Author Reflections: Bile Duct Resection-Is It Beneficial for Distal Cholangiocarcinoma? 61
33094374 2021
26
Stratification of Postoperative Prognosis by Invasive Tumor Thickness in Perihilar Cholangiocarcinoma. 61
33040247 2021
27
Safety and Oncological Benefit of Hepatopancreatoduodenectomy for Advanced Extrahepatic Cholangiocarcinoma with Horizontal Tumor Spread: Shinshu University Experience. 61
33044629 2021
28
ASO Author Reflections: Is Major Hepatopancreatoduodenectomy Beneficial for Patients with Advanced and Widespread Extrahepatic Cholangiocarcinoma? 61
33084991 2021
29
ASO Author Reflections: Tumor Burden in Intrahepatic Cholangiocarcinoma. 61
33393044 2021
30
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient. 61
33458846 2021
31
lncRNA SNHG16 Mediates Cell Proliferation and Apoptosis in Cholangiocarcinoma by Directly Targeting miR-146a-5p/GATA6 Axis. 61
33797690 2021
32
Oncologic Reappraisal of Bile Duct Resection for Middle-Third Cholangiocarcinoma. 61
32960392 2021
33
Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. 61
33617828 2021
34
[A prognostic model of intrahepatic cholangiocarcinoma after curative intent resection based on Bayesian network]. 61
33706443 2021
35
ASO Author Reflections: Can Invasive Tumor Thickness Stratify the Postoperative Prognosis of Perihilar Cholangiocarcinoma? 61
32935267 2021
36
ASO Author Reflections: Hepatobiliary Surgeons are Spurred to Implement Totally Minimally Invasive Techniques for Perihilar Cholangiocarcinoma Surgery. 61
33001301 2021
37
Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report. 61
33811313 2021
38
Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients. 61
33387086 2021
39
Development and validation of a CpG island methylator phenotype-related prognostic signature for cholangiocarcinoma. 61
32996133 2021
40
Intrahepatic cholangiocarcinoma as the new field of implementation of laparoscopic liver resection programs. A comparative propensity score-based analysis of open and laparoscopic liver resections. 61
32342213 2021
41
ASO Visual Abstract: Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy? 61
33386544 2021
42
LGR5 induces β-catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma. 61
33249719 2021
43
Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy? 61
33259043 2021
44
Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. 61
33415559 2021
45
OSchol: an online consensus survival web server for cholangiocarcinoma prognosis analysis. 61
32888851 2021
46
Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche. 61
33583626 2021
47
Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis. 61
32445050 2021
48
Intra-pancreatic distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: a common short and long-term prognosis? 61
33486711 2021
49
Total upper transversal hepatectomy with outflow reconstruction for advanced mass-forming cholangiocarcinoma. 61
33625678 2021
50
Changing ERCP position to help in differentiating Mirizzi syndrome from cholangiocarcinoma. 61
33301737 2021

Variations for Intrahepatic Cholangiocarcinoma

ClinVar genetic disease variations for Intrahepatic Cholangiocarcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 APC NM_000038.6(APC):c.4440G>C (p.Gln1480His) SNV Uncertain significance 482375 rs876659881 GRCh37: 5:112175731-112175731
GRCh38: 5:112840034-112840034
2 APC NM_000038.6(APC):c.8461G>A (p.Asp2821Asn) SNV Uncertain significance 559959 rs1554089164 GRCh37: 5:112179752-112179752
GRCh38: 5:112844055-112844055
3 APC NM_000038.6(APC):c.8332G>T (p.Ala2778Ser) SNV Uncertain significance 133537 rs587778046 GRCh37: 5:112179623-112179623
GRCh38: 5:112843926-112843926

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

Pathways related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 TP53 KRAS FGFR2 APC
2 10.87 TP53 KRAS IDH2 IDH1 FGFR2
3
Show member pathways
10.07 IDH2 IDH1

GO Terms for Intrahepatic Cholangiocarcinoma

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP metabolic process GO:0006739 9.16 IDH2 IDH1
2 isocitrate metabolic process GO:0006102 8.96 IDH2 IDH1
3 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
2 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....